Your browser doesn't support javascript.
loading
Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial.
Van Gaal, L F; Caterson, I D; Coutinho, W; Finer, N; Maggioni, A P; Sharma, A M; Torp-Pedersen, C; Ge, H; Moran, S A; Shepherd, G M; James, W P T.
Afiliação
  • Van Gaal LF; Department of Diabetology, Metabolism and Clinical Nutrition, Antwerp University Hospital, Belgium. luc.van.gaal@uza.be
Diabetes Obes Metab ; 12(1): 26-34, 2010 Jan.
Article em En | MEDLINE | ID: mdl-19758358
ABSTRACT

OBJECTIVE:

To assess treatment responses to sibutramine and weight management in diabetic patients during the lead-in period of the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.

METHODS:

SCOUT is an ongoing, prospective, randomized, double-blind, placebo-controlled outcome trial in cardiovascular high-risk overweight/obese patients. A total of 10 742 patients received single-blind sibutramine and individualized weight management during the 6-week lead-in period; 84% had a history of type 2 diabetes mellitus and additional co-morbidities. Post-hoc analyses assessed anthropomorphic and vital sign responses between patients with and without diabetes.

RESULTS:

Concomitant antidiabetic medication use was reported by 86% of the diabetic patients (approximately 30% required insulin-alone or in combination). Body weight and waist circumference decreased in diabetic patients median 2.1 kg; 2.0 cm (both men and women); for those on insulin 1.9 kg; 1.5/2.0 cm (men/women); without insulin 2.3 kg; 2.0 cm (both men and women); blood pressure (BP) was also reduced (median systolic/diastolic 3.5/1.0 mmHg) with larger reductions in diabetic patients who were hypertensive and/or lost the most weight (>5%). In diabetic patients who entered with BP at target (<130/<85 mmHg) but did not lose weight (N = 245), increases of 3.5/2.0 mmHg were observed. Non-diabetic patients had greater weight losses (2.5 kg) but smaller reductions in BP (systolic/diastolic -2.5/-0.5 mmHg). Pulse rate increases were less in diabetic vs. non-diabetic patients (1.5 vs. 2.0 bpm).

CONCLUSION:

In these high-risk diabetic patients, sibutramine and lifestyle modifications for 6 weeks resulted in small, but clinically relevant, median reductions in body weight, waist circumference and BP. A small median increase in pulse rate was recorded.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Depressores do Apetite / Ciclobutanos / Diabetes Mellitus Tipo 2 / Angiopatias Diabéticas / Obesidade Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2010 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Depressores do Apetite / Ciclobutanos / Diabetes Mellitus Tipo 2 / Angiopatias Diabéticas / Obesidade Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Diabetes Obes Metab Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2010 Tipo de documento: Article País de afiliação: Bélgica